Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Von Willebrand Disease (VWD) Clear all
Completed Phase 1 Interventional

To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

NCT04770935
View directory record Official record
Conditions
Von Willebrand's Disease (VWD)
Interventions
efanesoctocog alfa (BIVV001)
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

NCT03879135
View directory record Official record
Conditions
Von Willebrand Disease (VWD)
Interventions
rVWF, rFVIII
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
0 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 21, 2026, 3:59 PM EDT
Recruiting No phase listed Observational

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

NCT06610201
View directory record Official record
Conditions
Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3, Von Willebrand Disease, Type 2A, Von Willebrand Disease, Type 2M, Von Willebrand Disease, Type 2N
Interventions
Clinical outcomes of patients with VWD, Type 1, Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3
Other
Lead sponsor
Hemab ApS
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed No phase listed Observational

Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)

NCT02466789
View directory record Official record
Conditions
Von Willebrands Disease
Interventions
Not listed
Lead sponsor
Jonathan Roberts
Other
Eligibility
2 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

NCT01410227
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII)
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 21, 2026, 3:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT06754852
View directory record Official record
Conditions
Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Interventions
HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
Drug
Lead sponsor
Hemab ApS
Industry
Eligibility
16 Years to 69 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

NCT07115004
View directory record Official record
Conditions
Von Willebrand Disease (VWD)
Interventions
VGA039
Drug
Lead sponsor
Vega Therapeutics, Inc
Industry
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 4 Interventional

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

NCT00168090
View directory record Official record
Conditions
Von Willebrand Disease, Blood Coagulation Disorders, Blood Platelet Disorders, Hematologic Disease
Interventions
Blood coagulation Factor VIII and vWF, human
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Jul 21, 2026, 3:59 PM EDT
Recruiting No phase listed Observational

The Severe Von Willebrand Disease (sVWD) Patient Registry

NCT05437536
View directory record Official record
Conditions
VWD - Von Willebrand's Disease
Interventions
Not listed
Lead sponsor
VWD Connect Foundation
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Wellington, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

NCT04052698
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Jul 21, 2026, 3:59 PM EDT
Recruiting Phase 1 Interventional

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807
View directory record Official record
Conditions
Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Interventions
Emicizumab
Drug
Lead sponsor
Bleeding and Clotting Disorders Institute Peoria, Illinois
Other
Eligibility
0 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
12
States / cities
Orange, California • Redwood City, California • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Bleeding Assessment Tool (BAT)

NCT07560007
View directory record Official record
Conditions
Bleeding Disorder, Von Willebrand Disease (VWD)
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Terminated Phase 3 Interventional Results available

Minimize Menorrhagia in Women With Von Willebrand Disease

NCT02606045
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
recombinant von Willebrand factor, tranexamic acid
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jul 21, 2026, 3:59 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)

NCT00630448
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

NCT00816660
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

NCT04953884
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
Up to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed No phase listed Observational Results available

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

NCT04053699
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Von Willebrand Factor-Containing Product
Drug
Lead sponsor
Octapharma
Industry
Eligibility
66 Months and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Jul 21, 2026, 3:59 PM EDT
Not yet recruiting Phase 2 Interventional

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

NCT07575308
View directory record Official record
Conditions
Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
Interventions
ALN-6400
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Completed No phase listed Observational

T-TAS® wS Method Comparison

NCT06710262
View directory record Official record
Conditions
Antiplatelet Therapy, Healthy Donors, Von Willebrand Disease (VWD)
Interventions
T-TAS PL Assay
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
21 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jul 21, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial

NCT04344860
View directory record Official record
Conditions
Von Willebrand Diseases, Postpartum Hemorrhage
Interventions
Recombinant Von Willebrand factor, Tranexamic Acid Injection [Cyklokapron]
Drug
Lead sponsor
Nicoletta C Machin
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 21, 2026, 3:59 PM EDT
Completed No phase listed Observational

The Von Willebrand Disease (VWD) International Prophylaxis Study

NCT00557908
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
VWF/FVIII products
Drug
Lead sponsor
Skane University Hospital
Other
Eligibility
Not listed
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 21, 2026, 3:59 PM EDT
Recruiting Phase 3 Interventional

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

NCT05582993
View directory record Official record
Conditions
Von Willebrand Disease (VWD)
Interventions
Vonicog Alfa, ADVATE
Biological
Lead sponsor
Takeda
Industry
Eligibility
Up to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
11
States / cities
Birmingham, Alabama • Peoria, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 21, 2026, 3:59 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

NCT05776069
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
VGA039, Placebo
Drug · Other
Lead sponsor
Vega Therapeutics, Inc
Industry
Eligibility
12 Years to 60 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 21, 2026, 3:59 PM EDT
Completed No phase listed Observational

ATHN 9: Severe VWD Natural History Study

NCT03853486
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
108 participants
Timeline
2019 – 2026
U.S. locations
22
States / cities
Orange, California • Aurora, Colorado • Farmington, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 21, 2026, 3:59 PM EDT